AWA
FATE icon

Arete Wealth Advisors’s Fate Therapeutics FATE Stock Holding History

Arete Wealth Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$405K Buy
+150,000
New +$278K 0.03% 305

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arete Wealth Advisors's FATE Position: Q2 2026 in Review

Arete Wealth Advisors opened a new position in Fate Therapeutics (FATE) in Q2 2026: 150,000 shares worth $405K. The stake represents 0.03% of the portfolio and ranks #305 among its holdings.

156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Arete Wealth Advisors held 150,000 shares of Fate Therapeutics worth $405K as of Q2 2026.
  • Fate Therapeutics was a new Arete Wealth Advisors position in Q2 2026.
  • Fate Therapeutics made up 0.03% of Arete Wealth Advisors's portfolio in Q2 2026, its #305 holding.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Arete Wealth Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.